Jacqueline Wong

Mrs. Jacqueline Wong


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ISIrina Shevchenko
Irina Shevchenko
BLBernardette Jingfei Lee
Bernardette Jingfei Lee
DDDavina Daudu
Davina Daudu
JDJames Evan Dodd
James Evan Dodd
JWJacqueline Wong
Jacqueline Wong
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
Background: Femoral arteriotomy closure after peripheral angiography and intervention is commonly achieved using vascular closure devices (VCDs) or compression-based strategies; however, comparative randomised data in contemporary peripheral endovascular practice remain limited. Methods: In this prospective randomised trial, adults undergoing femoral-access diagnostic angiography or peripheral endovascular intervention were assigned in a 1:1 ratio to haemostasis with the FemoStop™ II Gold pneumatic compression system or a contemporary VCD strategy. The primary endpoint was a composite of major or minor groin-site complications immediately after sheath removal. Secondary endpoints included composite complications at recovery, discharge, and 30 days, with separate analyses of major and minor complications. Patient-reported pain was assessed using the Verbal Numerical Rating Scale (VNRS). Efficacy and safety analyses were performed according to the intention-to-treat and as-treated principles, respectively. Risk ratios were estimated using modified Poisson regression with robust variance, with prespecified adjustment for sex, systolic blood pressure before sheath removal, and sheath size. Results: A total of 130 participants underwent randomisation, including 66 assigned to FemoStop™ II Gold and 64 assigned to VCDs. The primary composite endpoint occurred in 23/66 participants (34.9%) in the FemoStop™ II Gold group and 16/64 (25.0%) in the VCD group (absolute difference, 9.9 percentage points; 95% confidence interval [CI], −6.1 to 25.7; p = 0.25), with the numerical difference driven predominantly by minor-only events (28.8% versus 15.6%; p = 0.09). At 30 days, the composite endpoint occurred in 17/66 participants (25.8%) and 12/64 participants (18.8%), respectively (absolute difference, 7.0 percentage points; 95% CI, −13.3 to 26.4; p = 0.40). Serious access-site events remained infrequent both immediately post-procedure (6.1% versus 9.4%; p = 0.53) and at 30 days (6.1% versus 4.7%; p = 0.72). The adjusted risk ratios were 1.28 (95% CI, 0.74 to 2.21) for the primary composite endpoint and 1.23 (95% CI, 0.63 to 2.40) for the 30-day composite endpoint. Ordinal VNRS pain distributions did not differ significantly at any timepoint, although “any pain” immediately post-procedure was less frequent with FemoStop™ II Gold (22.7% versus 40.6%; unadjusted risk ratio, 0.56; 95% CI, 0.33 to 0.93); this association was attenuated after adjustment (adjusted risk ratio, 0.63; 95% CI, 0.38 to 1.03). Prespecified interaction testing suggested that the effect of treatment on composite complications varied according to sheath size both immediately post-procedure and at 30 days (p < 0.001 for both interactions). Conclusions: In patients undergoing femoral-access diagnostic angiography or peripheral endovascular intervention, haemostasis with FemoStop™ II Gold resulted in 30-day groin-site complication rates that did not differ significantly from those observed with contemporary VCD strategies. Serious access-site events remained infrequent in both groups, and the apparent early reduction in patient-reported pain with FemoStop™ II Gold was not definitive after adjustment. Larger, adequately powered multicentre studies are warranted to clarify sheath size-dependent effects and uncommon clinically consequential vascular events.

Verified
Journal Article
Open access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
RMReane Macaulay
Reane Macaulay
DMDaniela Liezel Mwipatayi
Daniela Liezel Mwipatayi
RCRevathy Carnagarin
Revathy Carnagarin
RVRamon Lee Varcoe
Ramon Lee Varcoe
MSMarkus P SCHLAICH
Markus P SCHLAICH
Background/Objectives: Carotid–femoral pulse-wave velocity (cfPWV) is the reference-standard non-invasive measure of central arterial stiffness and a validated marker of cardiovascular risk in hypertension. While lipoprotein(a) [Lp(a)] and homocysteine have each been implicated in vascular injury, their independent and combined associations with arterial stiffness in treated hypertension remain uncertain. In this study, we examined the associations of Lp(a), homocysteine, and peripheral artery disease (PAD) with cfPWV and assessed whether concomitant elevation of Lp(a) and homocysteine was associated with excess arterial stiffness. Methods: We conducted a single-centre, cross-sectional study of 366 consecutive adults with treated hypertension attending a tertiary hypertension centre and associated vascular service between February 2016 and October 2019. cfPWV was measured non-invasively through applanation tonometry using the SphygmoCor XCEL system. Multivariable robust linear regression was used to assess associations with cfPWV after adjustment for age, sex, body mass index, mean 24 h systolic blood pressure (BP), diabetes mellitus, chronic kidney disease, smoking status, low-density lipoprotein cholesterol, and PAD. Joint associations and interactions on multiplicative and additive scales were also evaluated. Results: Of 366 participants, 99 (27.0%) had high arterial stiffness, defined as cfPWV ≥ 10 m/s. After full adjustment, cfPWV increased by 0.13 m/s per 0.1 g/L increase in Lp(a) (95% CI, 0.08 to 0.18; p < 0.001) and by 0.26 m/s per 5 μmol/L increase in homocysteine (95% CI, 0.02 to 0.49; p = 0.03). Participants with concomitantly elevated Lp(a) and homocysteine had the highest adjusted cfPWV, with a mean difference of 1.56 m/s versus the low-Lp(a)/low-homocysteine group (95% CI, 1.00 to 2.13; p < 0.001). No meaningful multiplicative or additive interaction was observed. Conclusions: In adults with treated hypertension, higher Lp(a), higher homocysteine, and PAD were independently associated with greater central arterial stiffness. Concomitant elevation of Lp(a) and homocysteine identified participants with the highest cfPWV without evidence of synergistic interaction, supporting a complementary vascular-risk model.

16 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
BLBernardette Jingfei Lee
Bernardette Jingfei Lee
DDDavina Daudu
Davina Daudu
IDIsabel Dwyer
Isabel Dwyer
DMDaniela Liezel Mwipatayi
Daniela Liezel Mwipatayi
JWJacqueline Wong
Jacqueline Wong
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
Background/Objectives: Drug-coated balloons (DCBs) provide local antiproliferative therapy during endovascular revascularization without leaving a permanent vascular scaffold. Sirolimus is an attractive cytostatic antiproliferative agent, although its relatively low lipophilicity creates challenges for rapid arterial uptake and sustained tissue residence following balloon delivery. The BRight DCB is a novel peripheral DCB coated with BIOtorcin™ (CRC-015), a highly lipophilic synthetic derivative of sirolimus. The BRight PK study primarily evaluated the systemic pharmacokinetics of BIOtorcin™ and its metabolite sirolimus following treatment of femoropopliteal disease and secondarily assessed procedural performance, safety, patency, and functional outcomes over 12 months. Methods: BRight PK was a prospective, single-center, non-randomized pharmacokinetic study involving six adults with symptomatic peripheral artery disease (PAD; Rutherford–Becker category 2–4) caused by de novo superficial femoral and/or proximal popliteal artery disease. Following mandatory predilatation, lesions were treated with one or two BRight DCBs. Whole-blood BIOtorcin™ and sirolimus concentrations were measured before treatment and serially from 5 min to 24 h after removal of the final DCB. Non-compartmental pharmacokinetic analysis was performed. Angiography and duplex ultrasound were independently assessed by a core laboratory, and endpoint-related clinical events were independently adjudicated. Results: All six participants completed 12-month follow-up. Mean age was 70.8 ± 7.4 years, and four (66.7%) were male. Seven BRight DCBs treated six lesions. Mean core-laboratory lesion length was 140.85 ± 136.23 mm, and baseline diameter stenosis was 78.50 ± 23.39%. Mean BIOtorcin™ exposure was 3976.8 ± 1665.7 µg (0.051 ± 0.0188 mg/kg). BIOtorcin™ Cmax was 23.60 ± 9.88 ng/mL at 5 min, terminal half-life was 21.87 ± 10.17 h, AUC0–t was 28.30 ± 12.19 h·ng/mL, and AUC0–∞ was 47.47 ± 18.27 h·ng/mL. Sirolimus Cmax was 0.692 ± 0.462 ng/mL at 24 h, when concentrations remained on the ascending portion of the concentration–time curve, indicating that the 24 h sampling window captured only early systemic sirolimus exposure rather than a complete pharmacokinetic profile. Device success was 100% (7/7); core-laboratory technical and procedural success were each 66.7% (4/6). No deaths, major or minor amputations, clinically driven target lesion revascularizations (cd-TLR), or clinically driven target vessel revascularizations (cd-TVRs) occurred. Visit-based 12-month primary patency was 83.3% (5/6); the single binary restenosis was detected at day 391, resulting in Kaplan–Meier primary patency of 100% at calendar day 365. The mean overall Walking Impairment Questionnaire (WIQ) score increased from 21.87 ± 19.16 at baseline to 62.28 ± 38.78 at 12 months. Conclusions: BIOtorcin™ demonstrated rapid systemic appearance following BRight DCB treatment, followed by a progressive decline in circulating parent drug concentrations and low systemic exposure to its metabolite, sirolimus. These pharmacokinetic findings, together with successful device delivery and the absence of major safety concerns over 12 months, demonstrate procedural feasibility and support continued clinical evaluation of the BRight DCB. Given the pharmacokinetic study design and small sample size (n = 6), the 12-month clinical, functional, and patency findings are exploratory and hypothesis-generating and should not be interpreted as evidence of clinical efficacy.